These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 10470208)

  • 1. Critical aspects related to the interpretation of the free-to-total PSA-ratio.
    Wolff JM; Stocker G; Borchers H; Haubeck H; Greiling H; Jakse G
    Anticancer Res; 1999; 19(4A):2633-6. PubMed ID: 10470208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total and free PSA: a methodical and clinical evaluation of five assays.
    Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
    Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
    Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The variation of percent free prostate-specific antigen determined by two different assays.
    Yang CR; Ou YC; Horng YY; Lee HS
    Anticancer Res; 2003; 23(1B):707-11. PubMed ID: 12680171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia.
    España F; Martínez M; Royo M; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF
    Eur Urol; 1997; 32(3):268-72. PubMed ID: 9358211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age related changes of free and total prostate specific antigen in serum.
    Wolff JM; Borchers H; Rohde D; Jakse G
    Anticancer Res; 1999; 19(4A):2629-32. PubMed ID: 10470207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA.
    Wolff JM; Boeckmann W; Effert PJ; Habib FK; Jakse G
    Anticancer Res; 1997; 17(4B):2993-4. PubMed ID: 9329583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The percentage of free prostate specific antigen used in detecting prostate cancer].
    Yang L; Fang Z; Song J; Deng S
    Zhonghua Wai Ke Za Zhi; 1999 Jan; 37(1):47-9. PubMed ID: 11829778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia.
    Nakamura T; Scorilas A; Stephan C; Jung K; Soosaipillai AR; Diamandis EP
    Cancer Res; 2003 Oct; 63(19):6543-6. PubMed ID: 14559849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical value of the Enzymun-Test for total and free PSA--a multicentre evaluation.
    Reiter W
    Anticancer Res; 1999; 19(6C):5559-62. PubMed ID: 10697616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related reference intervals for free and total prostate-specific antigen in a Singaporean population.
    Saw S; Aw TC
    Pathology; 2000 Nov; 32(4):245-9. PubMed ID: 11186419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
    Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical usefulness of free PSA/total PSA ratio in the early diagnosis of prostatic cancer].
    Laguna Pes MP; Guinda Sevillano C; Zazo Romojaro A; Domínguez J; García Luzón A; Borrego Hernando J; Gimeno Collado A
    Arch Esp Urol; 2000 May; 53(4):333-41. PubMed ID: 10900763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
    J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The analytical and clinical performance of the new Boehringer Mannheim Enzymun-Test PSA assay for prostate-specific antigen.
    Blijenberg BG; Eman I; Boevé ER; Mössner E; Uhl W
    Eur J Clin Chem Clin Biochem; 1995 Jun; 33(6):383-92. PubMed ID: 7578619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of free to total prostate specific antigen ratio in serum in the diagnosis of prostatic enlargement.
    Bhuiyan AK; Kibria SA; Subhan SS
    Bangladesh Med Res Counc Bull; 2004 Aug; 30(2):51-9. PubMed ID: 15813483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multigene methylation analysis for detection and staging of prostate cancer.
    Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.